Astrazeneca (AZN) Enterprise Value (2009 - 2026)
Astrazeneca (AZN) recorded quarterly Enterprise Value of -$7.9 billion in Q1 2026, down 27.91% quarter-over-quarter from -$6.2 billion in Q4 2025, and down 45.99% on a YoY basis from -$14.7 billion in Q1 2025.
Astrazeneca (AZN) Enterprise Value (2009 - 2026) Analysis & Trends
Astrazeneca's Enterprise Value history runs 18 years deep, the most recent figure standing at -$7.9 billion for Q1 2026.
- In Q1 2026, Enterprise Value fell 45.99% year-over-year to -$7.9 billion; the TTM figure through Mar 2026 stood at -$7.9 billion (down 45.99% YoY), while the FY2025 annual figure was -$6.2 billion, down 12.38% from the prior year.
- Enterprise Value was -$7.9 billion for Q1 2026 at Astrazeneca, down from -$6.2 billion in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$1.3 billion in Q4 2024 to a low of -$8.6 billion in Q3 2025.
- Historically, Enterprise Value has averaged -$6.0 billion across 5 years, with a median of -$6.0 billion in 2023.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value soared 78.98% in 2024, then plunged 395.93% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$6.3 billion in 2022, then advanced by 4.75% to -$6.0 billion in 2023, then jumped by 78.98% to -$1.3 billion in 2024, then slumped by 395.93% to -$6.2 billion in 2025, then slipped by 27.91% to -$7.9 billion in 2026.
- The last three Enterprise Value figures came in at -$7.9 billion (Q1 2026), -$6.2 billion (Q4 2025), and -$8.6 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | -4.96 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | -5.28 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | -22.05 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -9.35 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -5.65 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | -12.04 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | -7.73 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -12.77 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -10.45 Bn |
| 10 | Astrazeneca | 67.83 Bn | 59.89 Bn | 12.61 Bn | -7.94 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.94 Bn |
| Dec 31, 2025 | -6.21 Bn |
| Sep 30, 2025 | -8.65 Bn |
| Jun 30, 2025 | -7.57 Bn |
| Mar 31, 2025 | -5.44 Bn |
| Dec 31, 2024 | -1.25 Bn |
| Sep 30, 2024 | -5.12 Bn |
| Jun 30, 2024 | -7.13 Bn |
| Mar 31, 2024 | -8.05 Bn |
| Dec 31, 2023 | -5.96 Bn |
| Sep 30, 2023 | -5.02 Bn |
| Jun 30, 2023 | -5.83 Bn |
| Mar 31, 2023 | -6.10 Bn |
| Dec 31, 2022 | -6.25 Bn |
| Sep 30, 2022 | -4.17 Bn |
| Jun 30, 2022 | -4.64 Bn |
| Mar 31, 2022 | -5.85 Bn |
| Dec 31, 2021 | -6.41 Bn |
| Sep 30, 2021 | -7.16 Bn |
| Jun 30, 2021 | -15.69 Bn |